Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Cheng

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
An implantable, designed-for-human-use peripheral nerve stimulation and recording system for advanced prostheticsJohn R Lachapelle, Caroline K Bjune, Alexander L Kindle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
IEEE Transactions on Bio-Medical Engineering|March 18, 2022
Artificial Intelligence Enables Real-Time and Intuitive Control of Prostheses via Nerve InterfaceDiu Khue Luu, Anh Tuan Nguyen, Ming Jiang, et al.
Lancet (London, England)|December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 16, 2005
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patientsRobert A Schnoll, Randi L Rothman, Dustin B Wielt, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2019
Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning RegimensAshwin Shinde, Dongyun Yang, Paul Frankel, et al.
Translational Oncology|January 17, 2013
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT InhibitorsWeisheng Zhang, Brian B Haines, Clay Efferson, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
American Journal of Clinical Oncology|February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 StudyRoger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
The Journal of Clinical Investigation|May 10, 2016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancerJanice M Mehnert, Anshuman Panda, Hua Zhong, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
An implantable, designed-for-human-use peripheral nerve stimulation and recording system for advanced prostheticsJohn R Lachapelle, Caroline K Bjune, Alexander L Kindle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
IEEE Transactions on Bio-Medical Engineering|March 18, 2022
Artificial Intelligence Enables Real-Time and Intuitive Control of Prostheses via Nerve InterfaceDiu Khue Luu, Anh Tuan Nguyen, Ming Jiang, et al.
Lancet (London, England)|December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 16, 2005
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patientsRobert A Schnoll, Randi L Rothman, Dustin B Wielt, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2019
Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning RegimensAshwin Shinde, Dongyun Yang, Paul Frankel, et al.
Translational Oncology|January 17, 2013
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT InhibitorsWeisheng Zhang, Brian B Haines, Clay Efferson, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
American Journal of Clinical Oncology|February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 StudyRoger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
The Journal of Clinical Investigation|May 10, 2016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancerJanice M Mehnert, Anshuman Panda, Hua Zhong, et al.
Pageof 8